[HTML][HTML] Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA. 5 and BN. 1 subvariant dominance in the Republic of Korea: a …
DH Kim, MG Yoo, NY Kim, SY Choi… - Osong Public Health …, 2024 - ncbi.nlm.nih.gov
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment
in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and …
in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and …
[HTML][HTML] Effectiveness of paxlovid, an oral antiviral drug, against the Omicron BA. 5 variant in Korea: severe progression and death between July and November 2022
JM Kim, MG Yoo, SJ Bae, J Kim… - Journal of Korean …, 2023 - synapse.koreamed.org
Background Paxlovid is an oral antiviral drug that received emergency use authorization in
South Korea for the treatment of patients with mild-to-moderate coronavirus disease 2019 …
South Korea for the treatment of patients with mild-to-moderate coronavirus disease 2019 …
[HTML][HTML] Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized …
J Xu, J Song, Z Xie, J Yang, D Wu, F Liu, Y Zhao… - Medicine, 2023 - journals.lww.com
Background: Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult
patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to …
patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to …
[HTML][HTML] The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
H Park, YJ Park, HY Lee, M Yu, YJ Song… - Osong Public Health …, 2022 - ncbi.nlm.nih.gov
Objectives On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ ritonavir) as
a treatment method that could reduce the risk of hospitalization or death for patients with …
a treatment method that could reduce the risk of hospitalization or death for patients with …
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China
P Li, L Huang, R Han, M Tang, G Fei… - Expert Review of Anti …, 2024 - Taylor & Francis
ABSTRACT Background Since December 2022, the Omicron variant has led to a
widespread pandemic in China. The study was to explore the safety and effectiveness of …
widespread pandemic in China. The study was to explore the safety and effectiveness of …
[HTML][HTML] Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA. 4, BA. 5 and XBB …
EV Low, MD Pathmanathan, SK Chidambaram… - International Journal of …, 2023 - Elsevier
Objective To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
J Liu, X Pan, S Zhang, M Li, K Ma, C Fan… - The Lancet Regional …, 2023 - thelancet.com
Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …
Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China
W Yang, Y Peng, C Wang, H Cai, L Zhang… - Infection and Drug …, 2024 - Taylor & Francis
Introduction The purpose of this study was to compare the viral shedding time in patients
infected with the Omicron variant during Paxlovid therapy and conventional therapy and to …
infected with the Omicron variant during Paxlovid therapy and conventional therapy and to …
[HTML][HTML] COVID-19 rebound after Paxlovid treatment during Omicron BA. 5 vs BA. 2.12. 1 subvariant predominance period
Paxlovid was authorized by FDA to treat mild-to-moderate COVID-19. In May 2022, the
Centers for Disease Control and Prevention (CDC) issued a Health Alert Network Health …
Centers for Disease Control and Prevention (CDC) issued a Health Alert Network Health …
A case of the application of Paxlovid for a patient infected by the SARS-CoV-2 Omicron variant
L Zhang, M Wang, X Ye - Inflammation and Cell Signaling, 2023 - smartscitech.com
Abstract Coronavirus disease 2019 (COVID-19) is a new acute respiratory infectious
disease with high infectivity. To date,> 500 million cases of COVID-19 have been confirmed …
disease with high infectivity. To date,> 500 million cases of COVID-19 have been confirmed …